Cannabis compounds tested on immune cells from arthritis and lupus patients

NCT ID NCT06842316

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Régional d'Orléans Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 21, 2026 · Updated 17 times

Summary

This study looks at how natural cannabis compounds (like CBD and THC) affect immune cells from 100 people with chronic inflammatory diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease. Researchers will take a blood sample and expose the cells to different cannabis extracts in a lab to see if they reduce inflammation. The goal is to understand which cannabis profiles might help control immune responses, but this is not a treatment study—it is a lab-based observation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU d'ORLEANS
RECRUITING

Orléans, 45067, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ARTHRITIS, PSORIATIC ARTHRITIS, RHEUMATOID INFLAMMATORY BOWEL DISEASES INFLAMMATORY BOWEL DISEASES INFLAMMATORY DISORDER OF IMMUNE SYSTEM LUPUS ERYTHEMATOSUS, SYSTEMIC SJOGREN'S SYNDROME SJOGREN'S SYNDROME SPONDYLITIS, ANKYLOSING